There are currently 74 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Metastatic Breast Cancer participants are Texas, California, Florida and New York.
Scalp Cooling in MBC
NCT04986579
Recruiting
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Register for Updates
Enhancing Access to Supportive Services for Women of Color with Metastatic Breast Cancer
NCT06405828
Recruiting
Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered supportive care intervention for historically underserved populations of women with metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Mount Sinai Hospital, New York, New York
Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer AJCC V7
Register for Updates
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT04315233
Recruiting
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah +1 locations
Conditions: Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Register for Updates
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT02422641
Recruiting
Management of leptomeningeal disease (LMD) in patients with metastatic breast cancer is an area of unmet clinical need. High-dose methotrexate (HD-MTX) is known to have activity against breast cancer and in contrast to other systemic chemotherapeutics, it penetrates the blood brain barrier, targets areas of poor cerebrospinal fluid flow, may penetrate bulky leptomeningeal disease, and provide treatment to systemic disease burden. While two retrospective studies have suggested activity of HD-MTX... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +2 locations
Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Register for Updates
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04030507
Recruiting
This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Register for Updates
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195
Recruiting
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Ironwood Cancer and Research Centers, Chandler, Arizona +58 locations
Conditions: Metastatic Breast Cancer
Register for Updates
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
Recruiting
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama +5 locations
Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
Register for Updates
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
NCT05508906
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +15 locations
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
Register for Updates
A Study of Pembrolizumab and Cryoablation in People with Breast Cancer
NCT06246968
Recruiting
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinic Hospital Arizona, Phoenix, Arizona +12 locations
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT05892068
Recruiting
The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment. The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964
Recruiting
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC). Currently frontline therapy for pts with HR+ ABC is antihormonal therapy with an aromatase inhibitor or selective estrogen receptor degrader plus a CDK4/6i. The proposed trial is a randomized study to further evaluate the potential benefit of switching a frontline regimen at the time that a molecular signal, ctDNA, suggests progression pri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2024
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates